CD1D and B-cell non-Hodgkin lymphoma: As antibody blockade of CD1d-expressing tumors would similarly abrogate direct type II NKT recruitment, our TM40D cells may not be able to recruit type II NKT cells, as suggested in the B cell lymphoma study [51].